The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...

With orphan drugs typically being high value, the potential risk of stock losses should be a top concern for biotechs looking ...

The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % ...

Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...

FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH)ODD status may expedite drug candidate development and ...

Neurotech International has received positive feedback from the European Medicines Agency (EMA) on the company’s Orphan ...

and the E.U.’s European Medicines Agency (EMA). “The granting of Orphan Drug Designation in these two jurisdictions confirms that we are on a relatively rapid and cost-effective path to market ...

The European market for orphan drugs presents many opportunities and challenges for pharma companies. With over 30 million people in the EU living with rare diseases, the demand for innovative ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

CEO and managing director Dr Anthony Filippis said the company was delighted to have received the positive opinion for orphan designation of NTI164 in Rett syndrome for Europe. “There are no ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple ...